Gyre Therapeutics (GYRE) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neurogene (NGNE) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 10.4% versus a loss of 44.2%. Over five years, GYRE leads with a -77.5% price change compared with -78.3% for NGNE. Gyre Therapeutics is the larger company by market cap ($460.8 million vs $458.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | NGNE |
|---|---|---|
| Share price | $4.21 | $22.15 |
| Market cap | $460.79M | $458.53M |
| 1-day change | -6.86% | -3.40% |
| YTD return | -40.37% | +7.52% |
| 1-year return | -44.24% | +10.42% |
| 5-year return | -77.55% | -78.33% |
| Forward P/E | 70.17 | — |
| EPS (TTM) | $-0.31 | $-5.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $116.59M | $0 |
| Revenue growth (YoY) | +10.24% | -100.00% |
| Net income (latest FY) | $9.88M | $-90.35M |
| Gross margin | 95.35% | — |
| Operating margin | 9.85% | — |
| Net margin | 8.47% | — |
| 52-week high | $9.14 | $43.66 |
| 52-week low | $3.97 | $15.93 |
| Distance from 52-week high | -53.94% | -49.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +343.47% | +250.47% |
| Average volume | 181.04K | 307.78K |
| Shares outstanding | 109.45M | 20.70M |
| Employees | 625 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGNE has outperformed GYRE by 54.7 percentage points over the past year.
- Gyre Therapeutics grew revenue faster in its latest fiscal year (+10.24% vs -100.00%).
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
GYRE vs NGNE FAQ
Which is bigger, Gyre Therapeutics or Neurogene?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $460.79M compared with $458.53M for Neurogene (NGNE).
Which stock has performed better over the past year, GYRE or NGNE?
NGNE returned +10.42% over the past 12 months, compared with -44.24% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.